Nektar Therapeutics operates as a biopharmaceutical company.
Nektar Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.51|
|52 Week High||US$12.92|
|52 Week Low||US$26.75|
|1 Month Change||22.12%|
|3 Month Change||-2.88%|
|1 Year Change||-18.15%|
|3 Year Change||-72.02%|
|5 Year Change||-11.95%|
|Change since IPO||340.27%|
Recent News & Updates
Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party
At first glance, NKTR's 6-month chart looks horrible. Weak-handed retail investors see the chart and run for the hills. The cause of the decline is a first-rate "short & distort" scheme meant to reduce the share price for several reasons. Meanwhile, institutional holders remain rock solid and even increased positions. Conference call "teal leaves" reveal hints of positive study data. Simple math yields a late 2022 share price of $150-$200.
|NKTR||US Pharmaceuticals||US Market|
Return vs Industry: NKTR underperformed the US Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: NKTR underperformed the US Market which returned 33.6% over the past year.
Stable Share Price: NKTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NKTR's weekly volatility (5%) has been stable over the past year.
About the Company
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19
Is Nektar Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NKTR ($16.51) is trading below our estimate of fair value ($195.13)
Significantly Below Fair Value: NKTR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NKTR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: NKTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NKTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NKTR's PB Ratio (3.4x) is in line with the US Pharmaceuticals industry average.
How is Nektar Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NKTR's revenue (55.9% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: NKTR's revenue (55.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NKTR's Return on Equity is forecast to be high in 3 years time
How has Nektar Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NKTR is currently unprofitable.
Growing Profit Margin: NKTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NKTR is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare NKTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: NKTR has a negative Return on Equity (-52.41%), as it is currently unprofitable.
How is Nektar Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: NKTR's short term assets ($1.1B) exceed its short term liabilities ($131.0M).
Long Term Liabilities: NKTR's short term assets ($1.1B) exceed its long term liabilities ($335.4M).
Debt to Equity History and Analysis
Debt Level: NKTR is debt free.
Reducing Debt: NKTR currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NKTR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NKTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Nektar Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NKTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NKTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NKTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NKTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NKTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Howard Robin (68 yo)
Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...
CEO Compensation Analysis
Compensation vs Market: Howard's total compensation ($USD11.24M) is above average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.
Experienced Management: NKTR's management team is considered experienced (3.5 years average tenure).
Experienced Board: NKTR's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NKTR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.
Nektar Therapeutics's employee growth, exchange listings and data sources
- Name: Nektar Therapeutics
- Ticker: NKTR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.989b
- Shares outstanding: 183.80m
- Website: https://www.nektar.com
Number of Employees
- Nektar Therapeutics
- 455 Mission Bay Boulevard South
- San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/17 22:02|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.